| Send E-mail to: aepstein@usc.edu | | | Telephone: 323-442-1172 | Fax: 323-442-3049 | | Office: HMR 205 | Mail Code: 9092 HSC |
Education:
BA 1971 Biology - Wesleyan University, Middletown, CT.
MD 1978 Medicine - Stanford University School of Medicine, Stanford, CA
PhD 1979 Cancer Biology - Stanford University, Stanford, CA
Postdoctoral Research Fellowship:
1978 - 1980 Eleanor Roosevelt Institute for Cancer Research, University of Colorado Medical Center, Denver, CO.
Started at USC: 1984 Research Topics: Cancer Treatment, Immunology, Cancer Cell Biology
Research Description Major Areas of Research Interest Cell culture, heterotransplantation, cytogenetics, and biological characterization of the human malignant lymphomas and leukemias; Biochemistry and immunology of nuclear proteins; Production and clinical testing of monoclonal antibodies for the immunodiagnosis and therapy of cancer. Research In Progress Development of humanized TNT antibodies; generation of human antibody/fusion proteins consisting of human cytokines and chemokines for the immunotherapy of cancer; development of low toxicity human IL-2 mutant; generation of human vasopermeability antibody agent to enhance drug and antibody uptake in tumors; development of antibody/enzyme fusion proteins for ADEPT; development of TNT imaging agents for the detection of solid tumors.
10 Selected Publications:
Click here to view all the publications for this faculty
Flanagan ML,Arias RS,Hu P,Khawli LA,Epstein AL - Soluble Fc fusion proteins for biomedical research. - Methods Mol Biol [2007] ;378():33-52 PubMed
Sadun RE,Hsu WE,Zhang N,Nien YC,Bergfeld SA,Sabzevari H,Lutsiak ME,Khawli L,Hu P,Epstein AL - Fc-mOX40L fusion protein produces complete remission and enhanced survival in 2 murine tumor models. - J Immunother [2008] Apr;31(3):235-45 PubMed
Hu P,Arias RS,Sadun RE,Nien YC,Zhang N,Sabzevari H,Lutsiak ME,Khawli LA,Epstein AL - Construction and preclinical characterization of Fc-mGITRL for the immunotherapy of cancer. - Clin Cancer Res [2008] Jan 15;14(2):579-88 PubMed
Khawli LA,Hu P,Epstein AL - Cytokine, chemokine, and co-stimulatory fusion proteins for the immunotherapy of solid tumors. - Handb Exp Pharmacol [2008] ;(181):291-328 PubMed
Zhang N,Khawli LA,Hu P,Epstein AL - Lym-1-induced apoptosis of non-Hodgkin's lymphomas produces regression of transplanted tumors. - Cancer Biother Radiopharm [2007] Jun;22(3):342-56 PubMed
Sadun RE,Sachsman SM,Chen X,Christenson KW,Morris WZ,Hu P,Epstein AL - Immune signatures of murine and human cancers reveal unique mechanisms of tumor escape and new targets for cancer immunotherapy. - Clin Cancer Res [2007] Jul 1;13(13):4016-25 PubMed
Arias RS,Flanagan ML,Miller KD,Nien YC,Hu P,Gray D,Khawli LA,Epstein AL - RA8, a human anti-CD25 antibody against human Treg cells. - Hybridoma (Larchmt) [2007] Jun;26(3):119-30 PubMed
Zhang N,Sadun RE,Arias RS,Flanagan ML,Sachsman SM,Nien YC,Khawli LA,Hu P,Epstein AL - Targeted and untargeted CD137L fusion proteins for the immunotherapy of experimental solid tumors. - Clin Cancer Res [2007] May 1;13(9):2758-67 PubMed
Liu A,Hu P,Khawli LA,Epstein AL - B7.1/NHS76: a new costimulator fusion protein for the immunotherapy of solid tumors. - J Immunother [2006] Jul-Aug;29(4):425-35 PubMed
Flanagan ML,Khawli LA,Hu P,Epstein AL - H60/TNT-3 fusion protein activates NK cells in vitro and improves immunotherapeutic outcome in murine syngeneic tumor models. - J Immunother [2006] May-Jun;29(3):274-83 PubMed
| |
